01—Abstract
Summary
Summary of the 10-K filed March 31, 1998. Cited figures are marked; the original filing is the authoritative source.
Columbia/HCA Healthcare Corporation's 1997 10-K describes a year of sharp deterioration.
Revenues were essentially flat at $18.82 billiona (up 0.2%), but pretax income from continuing operations fell 84% to $388 million, with pretax margins collapsing to 2.1% from 13.0% in 1996. Excluding $442 million in asset impairment charges and $140 million in restructuring and investigation costs, pretax income would have been $970 million, still down about 60%. The company reported a net loss of $305 million for 1997, driven by a $443 million estimated after-tax loss on discontinued operations (home health, Value Health pharmacy and behavioral health units) and a $56 million cumulative accounting change charge.
Operating expense ratios rose across every category, with salaries and benefits at 40.6%b of revenue versus 38.4% in 1996, and the provision for doubtful accounts at 7.5% versus 6.4%. The filing is dominated by legal and regulatory risk. The company disclosed federal search warrants, grand jury-related subpoenas, an SEC formal investigation, and its own admission that it believes it is a target of the investigations.
It faces numerous qui tam False Claims Act suits, consolidated securities class actions, shareholder derivative suits in state and federal courts, and patient/payer class actions alleging billing fraud. Management states that it cannot predict the outcome, that adverse resolution could materially affect liquidity, financial position and results, and that the company is in compliance with its credit facility covenants. Credit ratings were cut during 1997 (senior debt to Baa2/BBB, then to Ba2 by Moody's in February 1998), and commercial paper access has been largely lost.
Long-term debt rose to $9.4 billionc from $7.0 billion, shifting toward bank borrowings, while stockholders' equity fell to $7.25 billion from $8.61 billion after a $1.0 billion share buyback. Management has begun a strategic overhaul: a change of CEO and COO, elimination of annual cash bonuses, divestiture of home health and most Value Health units (with Value Behavioral Health and Value Rx sales agreed for $230 million and $445 million), unwinding of physician hospital interests, and a review of restructuring alternatives that could include spin-offs and a smaller, more focused company.
No restructuring plan had been approved as of the filing date. For investors, the central questions are the size of eventual government settlements and judgments, whether margins can recover from the 1997 level, and how the restructuring will reshape the capital structure.
02—Key points
Key Highlights
- Pretax income from continuing operations fell 84.1% to $388 million in 1997, with pretax margin dropping to 2.1% from 13.0%; excluding $582 million of impairment and restructuring charges, it fell 60.3% to $970 million.
- Net loss of $305 million (-$0.46 per share) versus net income of $1.5 billion in 1996, reflecting a $443 million after-tax loss on discontinued operations and a $56 million cumulative accounting change charge.
- Revenues were flat at $18.82 billion (+0.2%); same-facility revenues grew 1.1%, but revenue per equivalent admission fell 2.4% amid rising managed care discounts and Medicare rate cuts.
- Operating cost ratios rose sharply: salaries and benefits to 40.6% of revenue (from 38.4%), other operating expenses to 22.6% (from 19.6%), and bad debt provisions to 7.5% (from 6.4%).
- Severe legal exposure: federal and state investigations, the company acknowledges it is a target, plus qui tam, securities class action, derivative and patient/payer suits; management cannot predict the outcome, and an adverse result could materially affect liquidity.
- Credit deterioration: senior debt downgraded to Baa2/BBB and later to Ba2 (Moody's, February 1998), commercial paper cut to P-3/A-3 and then NP, forcing a shift to $4.8 billion of bank borrowings; total long-term debt rose to $9.4 billion.
- Strategic restructuring under new management: divesting home health and most Value Health businesses, eliminating annual cash incentives, unwinding physician hospital interests, and evaluating a spin-off or a smaller, more focused company (no plan approved).
03—Questions
Frequently Asked Questions
Why did earnings collapse in 1997 and how much of the decline is one-time?
Pretax income from continuing operations fell to $388 million from $2.4 billion. About $582 million of the decline reflects non-recurring items: $442 million of asset impairments on facilities to be sold or closed and $140 million of restructuring and investigation costs. Excluding these, pretax income still fell about 60% to $970 million, due to slower revenue growth, falling revenue per admission, and operating expenses that management could not cut quickly enough.
What is the potential financial impact of the government investigations and lawsuits?
The filing does not quantify a liability. Management states the ultimate liabilities cannot be reasonably estimated as to timing or amount. Potential consequences include substantial fines, civil and criminal penalties, and exclusion from Medicare and Medicaid, which would be material given that Medicare and Medicaid represent about 40% of revenues. The filing also lists qui tam damages of up to three times false claims amounts plus per-claim penalties, and several class actions where the amounts claimed may be substantial.
Is the company at risk of financial strain or liquidity problems?
Liquidity is tighter. Commercial paper access was largely lost after downgrades, so borrowings shifted to bank credit facilities. Long-term debt reached $9.4 billion, up from $7.0 billion, and about $650 million of credit was available as of February 28, 1998. Management says it is in compliance with covenants and expects operating cash flow, bank facilities and expected asset sales to meet 1998 needs. Two bank facilities totaling $5.0 billion expire in June 1998 (364-day) and February 2002 (five-year), so refinancing risk is a concern. Capital expenditures of about $1.4 billion are planned for 1998, and there are $1.0 billion of joint venture put obligations.
What are the planned asset sales and restructuring, and what do they mean for investors?
The company plans to sell its home health business and three of four Value Health units. Value Behavioral Health ($230 million) and Value Rx ($445 million) have agreements expected to close in Q2 1998, with proceeds to repay bank debt. Management is also evaluating divestitures and spin-offs that could make it a smaller, more focused company, but no plan had been approved. Investors should note that spin-offs would need board and regulatory approval, and the final capital structure is undetermined.
Were there any changes to shareholder returns, dividends or share count?
The company repurchased about 29.4 million shares for $1.0 billion under a program completed in 1997, which reduced stockholders' equity to $7.25 billion from $8.61 billion. The quarterly dividend was $0.02 per share, and 1997 cash dividends totaled $0.07 per share, down from $0.08. Diluted earnings per share were a loss of $0.46 for the full year. The 1998 dividend policy was stated as intended to continue, but future payments depend on earnings and financial condition.
04—Continue